{
    "name": "ethambutol",
    "comment": "Rx",
    "other_names": [
        "Myambutol"
    ],
    "classes": [
        "Antitubercular Agents"
    ],
    "source": "https://reference.medscape.com/drug/myambutol-ethambutol-342677",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: enters breast milk; use with caution (AAP Committee states \"compatible with nursing\")"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: enters breast milk; use with caution (AAP Committee states \"compatible with nursing\")"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Known optic neuritis (unless clinical judgment determines that it may be used)",
                "Patients unable to appreciate and report visual side effects or changes in vision (eg, young children, unconscious patients)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May produce decreases in visual acuity which appear to be due to optic neuritis; effect may be related to dose and duration of treatment; effect is generally reversible when administration of drug is discontinued promptly; however, irreversible blindness has been reported",
                "Liver toxicities including fatalities reported; baseline and periodic assessment of hepatic function should be performed",
                "Not recommended for use in pediatric patients <13 years; safe conditions for use not established",
                "Patients with decreased renal function need dosage reduced as determined by serum levels of the drug; main path of excretion of this drug is by the kidneys",
                "Drug may have adverse effects on vision; physical examination should include ophthalmoscopy, finger perimetry and testing of color discrimination",
                "In patients with visual defects such as cataracts, recurrent inflammatory conditions of the eye, optic neuritis, and diabetic retinopathy, the evaluation of changes in visual acuity is more difficult, and care should be taken to be sure the variations in vision are not due to underlying disease conditions",
                "In such patients, consideration should be given to relationship between benefits expected and possible visual deterioration since evaluation of visual changes is difficult",
                "As with any potent drug, baseline and periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, should be performed"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "ethambutol decreases effects of BCG vaccine live by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "allopurinol",
            "description": {
                "common": "ethambutol decreases effects of allopurinol by Other (see comment). Use Caution/Monitor. \nComment: Hyperuricemia reported with ethambutol and precipitation of gout reported; uric acid lowering agents may be require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide increases levels of ethambutol by cation binding in GI tract. Use Caution/Monitor. Avoid administering aluminum hydroxide containing antacids for at least 4 hr following ethambutol dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide/magnesium carbonate",
            "description": {
                "common": "aluminum hydroxide/magnesium carbonate increases levels of ethambutol by cation binding in GI tract. Use Caution/Monitor. Avoid administering aluminum hydroxide containing antacids for at least 4 hr following ethambutol dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide/magnesium trisilicate",
            "description": {
                "common": "aluminum hydroxide/magnesium trisilicate increases levels of ethambutol by cation binding in GI tract. Use Caution/Monitor. Avoid administering aluminum hydroxide containing antacids for at least 4 hr following ethambutol dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "febuxostat",
            "description": {
                "common": "ethambutol decreases effects of febuxostat by Other (see comment). Use Caution/Monitor. \nComment: Hyperuricemia reported with ethambutol and precipitation of gout reported; uric acid lowering agents may be require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "ethambutol decreases effects of probenecid by Other (see comment). Use Caution/Monitor. \nComment: Hyperuricemia reported with ethambutol and precipitation of gout reported; uric acid lowering agents may be require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "ethambutol decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Acute gout or hyperuricemia",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "LFT abnormalities",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Optic neuritis",
            "percent": null
        },
        {
            "name": "symptoms may include decreased acuity",
            "percent": null
        },
        {
            "name": "color blindness or visual defects",
            "percent": null
        },
        {
            "name": "usually revrsible with discontinuation",
            "percent": null
        },
        {
            "name": "though irreversible blindness has been reported",
            "percent": null
        },
        {
            "name": "Peripheral neuritis",
            "percent": null
        },
        {
            "name": "Pruritis",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}